{"filing":{"accession_number":"0001493152-26-027201","cik":"0000749647","ticker":"IMNN","company_name":"Imunon, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/form8-k.htm"},"events":[{"id":6907,"run_id":6056,"accession_number":"0001493152-26-027201","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The Company closed a material transaction on June 4, 2026, as disclosed via press release. The specific nature of the transaction (acquisition, merger, or similar corporate action) is referenced but not detailed in the 8-K Items reviewed.","company_name":"Imunon, Inc.","ticker":"IMNN","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4460,"accession_number":"0001493152-26-027201","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the \"closing of the Transaction\" via press release on June 4, 2026. While the Item 7.01 section itself does not detail the transaction's nature, the language \"closing of the Transaction\" is a standard disclosure of completion of a material acquisition, merger, or similar corporate event. The capitalized \"Transaction\" and formal announcement via press release indicate a significant corporate action material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:45.830237+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":6908,"run_id":6056,"accession_number":"0001493152-26-027201","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Company issued unregistered Preferred Shares pursuant to Section 4(a)(2) of the Securities Act in a private placement, materially diluting existing shareholder equity and voting power.","company_name":"Imunon, Inc.","ticker":"IMNN","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4458,"accession_number":"0001493152-26-027201","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 explicitly discloses unregistered sales of equity securities (Preferred Shares) issued pursuant to Section 4(a)(2) of the Securities Act, which is a private placement exemption. This is a classic dilutive issuance event that would materially affect shareholder equity and voting power, particularly relevant for a small-cap biotech company like Imunon.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:45.830237+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":6909,"run_id":6056,"accession_number":"0001493152-26-027201","anchor_item_number":"5.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The Company filed a Certificate of Designation creating 400 shares of Series A Preferred Stock with a stated value of $12,000 per share, bearing an 8% annual preferred return and subject to redemption at 110% of liquidation value, representing a material capital structure change.","company_name":"Imunon, Inc.","ticker":"IMNN","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4459,"accession_number":"0001493152-26-027201","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company filed a Certificate of Designation creating 400 shares of Series A Preferred Stock with a stated value of $12,000 per share (total ~$4.8M), bearing an 8% annual preferred return and subject to redemption at 110% of liquidation value. While Item 5.03 covers amendments to articles and bylaws, this disclosure centers on the creation of a new class of preferred equity with material financial terms (preferred return, redemption rights, default provisions) rather than a routine bylaw amendment. This is a material capital structure change that would affect investor assessment of the company's capitalization and obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:45.830237+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":6910,"run_id":6056,"accession_number":"0001493152-26-027201","anchor_item_number":"2.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"summary":"The Company created a direct financial obligation whose specific nature is incorporated by reference from Item 1.01 and cannot be precisely determined from the available Item classifications.","company_name":"Imunon, Inc.","ticker":"IMNN","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4457,"accession_number":"0001493152-26-027201","item_number":"2.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, but the actual substance is incorporated by reference from Item 1.01. Without access to Item 1.01's content, the specific nature of the obligation cannot be determined—it could relate to M\u0026A activity, debt issuance, lease arrangements, or other material transactions. The reference structure prevents precise classification into a more specific event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:45.830237+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4457,"accession_number":"0001493152-26-027201","item_number":"2.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, but the actual substance is incorporated by reference from Item 1.01. Without access to Item 1.01's content, the specific nature of the obligation cannot be determined—it could relate to M\u0026A activity, debt issuance, lease arrangements, or other material transactions. The reference structure prevents precise classification into a more specific event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:45.830237+00:00","company_name":"Imunon, Inc.","ticker":"IMNN","filing_date":"2026-06-04"},{"id":4458,"accession_number":"0001493152-26-027201","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 explicitly discloses unregistered sales of equity securities (Preferred Shares) issued pursuant to Section 4(a)(2) of the Securities Act, which is a private placement exemption. This is a classic dilutive issuance event that would materially affect shareholder equity and voting power, particularly relevant for a small-cap biotech company like Imunon.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:45.830237+00:00","company_name":"Imunon, Inc.","ticker":"IMNN","filing_date":"2026-06-04"},{"id":4459,"accession_number":"0001493152-26-027201","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company filed a Certificate of Designation creating 400 shares of Series A Preferred Stock with a stated value of $12,000 per share (total ~$4.8M), bearing an 8% annual preferred return and subject to redemption at 110% of liquidation value. While Item 5.03 covers amendments to articles and bylaws, this disclosure centers on the creation of a new class of preferred equity with material financial terms (preferred return, redemption rights, default provisions) rather than a routine bylaw amendment. This is a material capital structure change that would affect investor assessment of the company's capitalization and obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:45.830237+00:00","company_name":"Imunon, Inc.","ticker":"IMNN","filing_date":"2026-06-04"},{"id":4460,"accession_number":"0001493152-26-027201","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the \"closing of the Transaction\" via press release on June 4, 2026. While the Item 7.01 section itself does not detail the transaction's nature, the language \"closing of the Transaction\" is a standard disclosure of completion of a material acquisition, merger, or similar corporate event. The capitalized \"Transaction\" and formal announcement via press release indicate a significant corporate action material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:45.830237+00:00","company_name":"Imunon, Inc.","ticker":"IMNN","filing_date":"2026-06-04"}]}